Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06 2024 - 3:30PM
Business Wire
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced that on February 15, 2024, the
Compensation Committee of Guardant’s Board of Directors approved
the granting of restricted stock units (“RSUs”) representing
218,236 shares of its common stock to 82 new non-executive
employees and non-qualified stock option awards to purchase an
aggregate of 29,048 shares of its common stock to one new
non-executive employee with a grant date of February 26, 2024 under
the Guardant Health, Inc. 2023 Employment Inducement Incentive
Award Plan (the “Inducement Plan”). Additionally, the Compensation
Committee approved an RSU award representing 52,136 shares of
common stock and a non-qualified stock option award to purchase an
aggregate of 78,204 shares of common stock to Terilyn Juarez Monroe
under the Inducement Plan who joined Guardant as its Chief People
Officer, in connection with her commencement of employment. The
RSUs and stock options were granted as inducements material to the
employees entering into employment with Guardant in accordance with
Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of equity
awards to individuals who were not previously employees of
Guardant, or following a bona fide period of non-employment, as an
inducement material to such individuals’ entering into employment
with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).
One-third of the shares underlying each RSU award vest on an
annual basis on the anniversary of the vesting commencement date,
subject to each employee’s continued employment with Guardant as of
each such vesting date. The RSUs are subject to the terms and
conditions of the Inducement Plan and the terms and conditions of a
RSU award agreement covering the grant.
All stock options have an exercise price of $20.14 per share,
which is equal to the closing price of Guardant’s common stock on
The Nasdaq Global Select Market on February 26, 2024. One-third of
the shares underlying each stock option award vest on the one-year
anniversary of the vesting commencement date and continue to vest
monthly thereafter over 24 months, subject to each employee’s
continued employment with Guardant as of each such vesting date.
The stock options are subject to the terms and conditions of the
Inducement Plan and the terms and conditions of a stock option
award agreement covering the grant.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
tests, vast data sets and advanced analytics. The Guardant Health
oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched Guardant360®, Guardant360 CDx,
Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI®
tests for advanced stage cancer patients, and Guardant Reveal™ for
early-stage cancer patients. The Guardant Health screening
portfolio, including the Shield™ test, aims to address the needs of
individuals eligible for cancer screening. For more information,
visit guardanthealth.com and follow the company on LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240306258727/en/
Investor Contact: investors@guardanthealth.com
Media Contact: Melissa Marasco press@guardanthealth.com
+1 650-647-3711
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Apr 2024 to May 2024
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From May 2023 to May 2024